MTA1-DT: A Drug Target / Disease Biomarker (G100507437)

Target Name: MTA1-DT

NCBI ID: G100507437

MTA1-DT

Other Name(s): MTA1-DT variant 1 | MTA1 divergent transcript | MTA1 divergent transcript, transcript variant 1

MTA1-DT: A Drug Target / Disease Biomarker

MTA1-DT is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the transmembrane protein family, which means that it spans the cell membrane and extends into the space between cells.

One of the interesting features of MTA1-DT is its role in the immune system. It is a key regulator of the complement system, which is a group of proteins that work together to help the body fight off infections. The complement system plays a crucial role in the immune response by helping to attract and destroy foreign particles that have entered the body.

Another important function of MTA1-DT is its role in cell signaling. It is a signaling protein that is involved in a variety of cellular processes, including cell growth, differentiation, and inflammation. It is able to communicate with other proteins and molecules in the cell to regulate their activity and influence the behavior of the cell.

MTA1-DT is also of interest as a potential drug target. Its role in the immune system and its involvement in cell signaling make it a potential target for small molecules that can modulate its activity. This has led to a great deal of research into the use of small molecules as potential therapeutic agents for a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative disorders.

One of the most promising areas of research into MTA1-DT is its potential as a treatment for cancer. Studies have shown that MTA1-DT has the potential to be a valuable therapeutic agent for cancer treatment. By modulating its activity, researchers hope to be able to reduce the growth of cancer cells and inhibit their spread to other parts of the body.

In addition to its potential as a cancer therapeutic, MTA1-DT is also of interest as a potential biomarker for the disease. Its role in the immune system and its expression in various tissues make it a potential indicator of the presence of cancer cells in the body. This has led to the development of techniques for using MTA1-DT as a diagnostic marker for cancer, as well as the potential for using it as a target for cancer immunotherapy.

Overall, MTA1-DT is a protein that has a wide range of functions in the body, including its role in the immune system and its involvement in cell signaling. Its potential as a drug target and as a biomarker for cancer make it an important area of research for scientists and clinicians alike.

Protein Name: MTA1 Divergent Transcript

The "MTA1-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTA1-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets